Nomination Committee appointed for the 2027 Annual General Meeting in SyntheticMR AB (publ)

In accordance with the instructions for the Nomination Committee adopted at the 2026 Annual General Meeting, the following shareholders have appointed representatives to the Nomination Committee ahead of the 2027 Annual General Meeting:

Swedia Invest AB: Elisabet Tunón

Marcel Warntjes: Marcel Warntjes

Panasari AB: Pia Engholm

Together, the above shareholders represent approximately 35 percent of the shares and votes in the company.

Elisabet Tunón, Marcel Warntjes and Pia Engholm are independent in relation to the company and its executive management. Marcel Warntjes and Pia Engholm are independent in relation to Swedia Invest AB, the company's largest shareholder in terms of voting rights among shareholders acting together in the management of the company.

The Nomination Committee is responsible for submitting proposals to the 2027 Annual General Meeting regarding the Chair of the Annual General Meeting, the Chair of the Board of Directors and other Board members, as well as fees and other remuneration to the Board members.

The Nomination Committee shall also submit proposals regarding the election and remuneration of auditors. Furthermore, the Nomination Committee shall propose a procedure for appointing the Nomination Committee ahead of the 2028 Annual General Meeting.

Shareholders wishing to submit proposals to the Nomination Committee may do so by email to Elisabet Tunón at lisa@swediacapital.se .

SyntheticMR AB (publ) develops and markets medical device *imaging solutions** designed to enhance efficiency and diagnostic precision in neuroimaging. The company offers a comprehensive product portfolio, including the SyMRI® solution, which measures absolute brain tissue properties and, from a single fast scan, generates multiple contrast-weighted images, performs automated biomarker segmentation, and provides quantitative data, as well as the AI-powered cNeuro® product suite, which supports clinicians in the assessment and management of neurological disorders.

The company is listed on the Spotlight Stock Market in Stockholm and is headquartered in Linköping, Sweden, with an additional office in Tampere, Finland. For more information, visit syntheticmr.com and combinostics.com.

**Regulatory clearances may vary by product and version, and indications for use may differ between countries/regions.*